Aceto Corporation (ACET): Price and Financial Metrics
ACET Price/Volume Stats
| Current price | $1.48 | 52-week high | $3.77 |
| Prev. close | $1.48 | 52-week low | $1.05 |
| Day low | $1.46 | Volume | 239,600 |
| Day high | $1.59 | Avg. volume | 1,289,251 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $1.84 | Market Cap | 121.62M |
ACET Stock Price Chart Interactive Chart >
Aceto Corporation (ACET) Company Bio
Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.
Latest ACET News From Around the Web
Below are the latest news stories about ADICET BIO INC that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Reports Third Quarter 2023 Financial Results and Provides Business UpdatesREDWOOD CITY, Calif. & BOSTON, November 08, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023. |
Adicet Bio to Present at the 2023 Jefferies London Healthcare ConferenceREDWOOD CITY, Calif. & BOSTON, November 07, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London. |
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual MeetingREDWOOD CITY, Calif. & BOSTON, November 02, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023. |
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif. & BOSTON, October 31, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted an inducement award on October 31, 2023. |
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics ConferenceREDWOOD CITY, Calif. & BOSTON, October 04, 2023--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Bos |
ACET Price Returns
| 1-mo | 10.45% |
| 3-mo | 5.71% |
| 6-mo | -27.80% |
| 1-year | -12.94% |
| 3-year | -80.55% |
| 5-year | -97.91% |
| YTD | -21.69% |
| 2023 | -78.86% |
| 2022 | -48.89% |
| 2021 | 24.48% |
| 2020 | 34.71% |
| 2019 | N/A |
Loading social stream, please wait...